MWNA
SPRY icon

Marshall Wace North America’s ARS Pharmaceuticals SPRY Stock Holding History

Marshall Wace North America’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.62M Buy
+162,183
New +$4M 0.01% 784
2021
Q1 		– Sell
-58,788
Closed -$2.72M – 1761
2020
Q4 		$2.72M Buy
+58,788
New +$1.96M 0.01% 682

Other funds holding SPRY

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace North America's SPRY Position: Q3 2021 in Review

Marshall Wace North America opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2021: 162,183 shares worth $1.62M. The stake represents 0.01% of the portfolio and ranks #784 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in SPRY as recently as Q4 2020.

Marshall Wace North America first reported a position in SPRY in Q4 2020 and has held it in 2 quarters since. The position peaked at $2.72M in Q4 2020. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • Marshall Wace North America held 162,183 shares of ARS Pharmaceuticals worth $1.62M as of Q3 2021.
  • ARS Pharmaceuticals was a new Marshall Wace North America position in Q3 2021.
  • ARS Pharmaceuticals made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #784 holding.
  • Marshall Wace North America first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 2 quarters since.
  • Marshall Wace North America's ARS Pharmaceuticals position peaked at $2.72M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.